טוען...

Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer

Plasma genotyping identifies potentially actionable mutations at variable mutant allele frequencies, often admixed with multiple subclonal variants, highlighting the need for their clinical and functional validation. We prospectively monitored plasma genotypes in 143 women with endocrine-resistant m...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:NPJ Precis Oncol
Main Authors: Medford, Arielle J., Dubash, Taronish D., Juric, Dejan, Spring, Laura, Niemierko, Andrzej, Vidula, Neelima, Peppercorn, Jeffrey, Isakoff, Steven, Reeves, Brittany A., LiCausi, Joseph A., Wesley, Benjamin, Malvarosa, Giuliana, Yuen, Megan, Wittner, Ben S., Lawrence, Michael S., Iafrate, A. John, Ellisen, Leif, Moy, Beverly, Toner, Mehmet, Maheswaran, Shyamala, Haber, Daniel A., Bardia, Aditya
פורמט: Artigo
שפה:Inglês
יצא לאור: Nature Publishing Group UK 2019
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6635494/
https://ncbi.nlm.nih.gov/pubmed/31341951
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41698-019-0090-5
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!